Lineage Cell Therapeutics
LCTX
LCTX
115 hedge funds and large institutions have $83M invested in Lineage Cell Therapeutics in 2023 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.
Holders
115
Holders Change
+11
Holders Change %
+10.58%
% of All Funds
1.69%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
15
Increased
27
Reduced
25
Closed
4
Calls
$15K
Puts
$1K
Net Calls
+$14K
Net Calls Change
-$50K
Top Buyers
| 1 |
1
Morgan Stanley
New York
|
$1.04M |
| 2 |
RA
2
Raffles Associates
New York
|
$2.32M |
| 3 |
3
Citadel Advisors
Miami,
Florida
|
$640K |
| 4 |
4
Geode Capital Management
Boston,
Massachusetts
|
$3.2M |
| 5 |
5
Barclays
London,
United Kingdom
|
$200K |
Top Sellers
| 1 |
1
BlackRock
New York
|
$9.3M |
| 2 |
LCM
2
Laurion Capital Management
New York
|
$473K |
| 3 |
DC
3
Defender Capital
Charlotte,
North Carolina
|
$5.42M |
| 4 |
MCM
4
MAI Capital Management
Independence,
Ohio
|
$876K |
| 5 |
5
Citigroup
New York
|
$26K |
